Name (Synonyms) | Correlation | |
---|---|---|
drug2577 | Two doses of placebo at the routine vaccination schedule Wiki | 1.00 |
drug2576 | Two doses of placebo at the emergency vaccination schedule Wiki | 1.00 |
drug2573 | Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki | 1.00 |
drug1134 | Hyperbaric Chamber Wiki | 1.00 |
drug2570 | Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki | 1.00 |
drug2574 | Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.
Description: Occurence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: From the beginning of the vaccination to 28 days after the whole schedule vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule (day 0,14) Time: The 14th day after two doses of vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28) Time: The 28th day after two doses of vaccinationDescription: Occurence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: 0~7 days after each dose injectionDescription: Safety index, abnormal changes will be defined as any one of the lab indexes experiencing changes out of clinical reference value range.
Measure: Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte) Time: The 3rd day after each dose injectionDescription: Occurence of SAEs post vaccination
Measure: Safety indexes of serious adverse events (SAEs) Time: From the beginning of the vaccination to 6 months after two doses of vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates Time: 7,14,21,42 days after the first dose injection for emergency vaccination schedule and 28,35,42 days after the first dose injection for the routine vaccination schedulesDescription: The seropositivity rates of IgG antibody tested by ELISA serum
Measure: Immunogenicity indexes of IgG antibody seropositivity rates Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The seropositivity rates of IgM antibody tested by ELISA serum
Measure: Immunogenicity indexes IgM antibody seropositivity rates Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The GMT of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of GMT of neutralizing-antibody Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The GMR of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of GMR of neutralizing-antibody Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: specific cellular immune responses
Measure: Immunogenicity indexes of cellular immune Time: The 14th day after each dose vaccinationDescription: he seropositivity rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody persistence Time: 6 months after two doses of vaccinationDescription: The GMT of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody GMT Time: 6 months after two doses of vaccinationDescription: Seropositivity rates of antinuclear antibody in serum
Measure: Safety indexes-Seropositivity rates of antinuclear antibody Time: The 7th day after each dose injectionDescription: Level of Inflammatory factors in serum
Measure: Safety indexes-Level of Inflammatory factors Time: The 7th day after each dose injection